What is HC Wainwright’s Estimate for TERN Q3 Earnings?

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) – Analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Terns Pharmaceuticals in a report issued on Thursday, September 4th. HC Wainwright analyst A. Fein anticipates that the company will earn ($0.35) per share for the quarter. HC Wainwright currently has a “Neutral” rating and a $7.44 target price on the stock. The consensus estimate for Terns Pharmaceuticals’ current full-year earnings is ($1.19) per share. HC Wainwright also issued estimates for Terns Pharmaceuticals’ Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.25) EPS, Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.48) EPS, FY2027 earnings at ($1.62) EPS, FY2028 earnings at ($0.62) EPS and FY2029 earnings at ($0.47) EPS.

Separately, BMO Capital Markets reduced their target price on Terns Pharmaceuticals from $26.00 to $15.00 and set an “outperform” rating on the stock in a report on Tuesday, May 13th. Three research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $15.61.

Terns Pharmaceuticals Stock Performance

TERN opened at $7.55 on Monday. The firm has a market cap of $660.70 million, a P/E ratio of -7.26 and a beta of -0.04. Terns Pharmaceuticals has a 52-week low of $1.87 and a 52-week high of $11.40. The business’s fifty day moving average is $6.06 and its 200-day moving average is $4.18.

Terns Pharmaceuticals (NASDAQ:TERN) last released its earnings results on Tuesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.02.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Thrive Wealth Management LLC acquired a new stake in shares of Terns Pharmaceuticals during the first quarter valued at about $29,000. Vontobel Holding Ltd. acquired a new stake in shares of Terns Pharmaceuticals during the first quarter valued at about $39,000. Engineers Gate Manager LP acquired a new stake in shares of Terns Pharmaceuticals during the second quarter valued at about $41,000. Canada Pension Plan Investment Board acquired a new stake in shares of Terns Pharmaceuticals during the second quarter valued at about $46,000. Finally, LeConte Wealth Management LLC acquired a new stake in shares of Terns Pharmaceuticals during the second quarter valued at about $47,000. Institutional investors own 98.26% of the company’s stock.

Insider Transactions at Terns Pharmaceuticals

In other Terns Pharmaceuticals news, CEO Amy L. Burroughs bought 23,314 shares of the firm’s stock in a transaction on Wednesday, June 25th. The shares were purchased at an average price of $3.87 per share, for a total transaction of $90,225.18. Following the completion of the transaction, the chief executive officer directly owned 47,083 shares in the company, valued at approximately $182,211.21. The trade was a 98.09% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Andrew Gengos bought 10,000 shares of the firm’s stock in a transaction on Friday, June 27th. The stock was acquired at an average price of $3.93 per share, for a total transaction of $39,300.00. Following the transaction, the chief financial officer owned 25,000 shares of the company’s stock, valued at approximately $98,250. The trade was a 66.67% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 48,314 shares of company stock worth $186,575. Company insiders own 1.50% of the company’s stock.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.